Combined allogeneic tumor cell vaccination and systematic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice

Journal of Experimental Medicine

Volumn 194, Issue 9, 2001, Pages 1195-1205

  Nanni, Patrizia ^a   Nicoletti, Giordano ^a,b   De Giovanni, Carla ^a   Landuzzi, Lorena ^a,b   Di Carlo, Emma ^c   Cavallo, Federica ^d,e   Pupa, Serenella M ^f   Rossi, Ilaria ^a   Colombo, Mario P ^f   Ricci, Cinzia ^a   Astolfi, Annalisa ^a   Musiani, Piero ^c   Forni, Guido ^d,e   Lollini, Pier Luigi ^a,g  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b IST Biotechnology Satellite Unit   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e MOLINETTE HOSPITAL   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g Istituto di Cancerologia   (Italy)

Author keywords

Allogeneic vaccine; HER 2 neu; IL 12; Mammary carcinoma

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 4; RECOMBINANT INTERLEUKIN 12; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PREVENTION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; TISSUE SPECIFICITY; TRANSGENIC MOUSE; TUMOR CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BREAST; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELL TRANSPLANTATION; FEMALE; IMMUNITY, CELLULAR; INTERFERON TYPE II; INTERLEUKIN-12; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, TRANSGENIC; RATS; RECEPTOR, ERBB-2; TRANSPLANTATION, HOMOLOGOUS; TUMOR CELLS, CULTURED; VACCINATION;

EID: 0035163903     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.194.9.1195     Document Type: Article

References (33)

1. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene
2. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice
3. Adoptive immunotherapy prevents prostate cancer in a transgenic animal model
4. Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer
5. Genetic immunization against neu/erbB2 transgenic breast cancer
6. HER,-2/neu is a tumor rejection target in tolerized HER,-2/neu transgenic mice
7. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice
8. Spontaneous mammary carcinomas fail to induce an immune response in syngeneic FVBN202 neu transgenic mice
9. Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin
10. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease
11. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma
12. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice
13. Expression of HER/erbB family of receptor tyrosine kinases and induction of differentiation by glial growth factor 2 in human rhabdomyosarcoma cells
14. Proteinase expression in early mouse embryos is regulated by leukaemia inhibitory factor and epidermal growth factor
15. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor, and y-interferon gene or admixed with conventional adjuvants
16. Synergistic interaction of the Neu proto-oncogene product and transforming growth factor α in the mammary epithelium of transgenic mice
17. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostilnulatory dendritic cells
18. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity
19. Inhibition of angiogenesis in vivo by interleukin 12
20. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12
21. Prevention of breast tumour development in vivo by downregulation of the p185neu receptor
22. A subclass of tumorinhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors
23. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice
24. Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast
25. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma
26. Spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice
27. IFN-γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
28. Interleukin 12-activated lymphocytes influence tumor genetic programs
29. Inhibition of interferon-γ may suppress allograft reactivity by T lymphocytes in vitro and in vivo
30. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo
31. IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases
32. IFN-γ can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen
33. Inhibition of tumor growth and enhancement of metastasis after transfection of the γ-interferon gene